Vision blue Pregnancy Warnings
This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.
US FDA pregnancy category: C
Animal studies have revealed evidence of fetal anomalies (e.g., cardiovascular, eye, neural tube, tail, and/or vertebral defects), increased post-implantation mortality, decreased fetal weight, and increased abortions in single, IV, intraperitoneal, or subcutaneous doses of 25 to 50 mg/kg administered during embryogenesis. There are no controlled data in human pregnancy.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
See references
